Significant pharmacokinetic interactions between artemether/lumefantrine and efavirenz or nevirapine in HIV-infected Ugandan adults

Journal of Antimicrobial Chemotherapy

Volumn 67, Issue 9, 2012, Pages 2213-2221

  Byakika Kibwika, Pauline ^a,b,c   Lamorde, Mohammed ^a,b   Mayito, Jonathan ^c   Nabukeera, Lillian ^a   Namakula, Rhoda ^a   Mayanja Kizza, Harriet ^a,c   Katabira, Elly ^a,c   Ntale, Muhammad ^a   Pakker, Nadine ^c   Ryan, Mairin ^b   Hanpithakpong, Warunee ^d   Tarning, Joel ^d,e   Lindegardh, Niklas ^d,e   De vries, Peter J ^f   Khoo, Saye ^g   Back, David ^g   Merry, Concepta ^a,b,c  

^a MAKERERE UNIVERSITY   (Uganda)

^b TRINITY COLLEGE DUBLIN   (Ireland)

^c Research in Africa   (Uganda)

^d MAHIDOL UNIVERSITY   (Thailand)

^e UNIVERSITY OF OXFORD   (United Kingdom)

^f ACADEMIC MEDICAL CENTER   (Netherlands)

^g UNIVERSITY OF LIVERPOOL   (United Kingdom)

Author keywords

Antimalarial; Antiretroviral; Drugs; Malaria

Indexed keywords

ARTEMETHER PLUS BENFLUMETOL; BENFLUMETOL; DIHYDROARTEMISININ; EFAVIRENZ; EMTRICITABINE PLUS TENOFOVIR DISOPROXIL; LAMIVUDINE; NEVIRAPINE; ZIDOVUDINE;

ADULT; AREA UNDER THE CURVE; ARTICLE; CLINICAL ARTICLE; CROSSOVER PROCEDURE; DRUG BLOOD LEVEL; DRUG DISTRIBUTION; DRUG HALF LIFE; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MALE; MAXIMUM PLASMA CONCENTRATION; PATIENT COMPLIANCE; PLASMA CONCENTRATION-TIME CURVE; TIME TO MAXIMUM PLASMA CONCENTRATION; UGANDA;

ADULT; ANTI-HIV AGENTS; ANTIMALARIALS; ARTEMISININS; BENZOXAZINES; CROSS-OVER STUDIES; DRUG COMBINATIONS; DRUG INTERACTIONS; ETHANOLAMINES; FEMALE; FLUORENES; HIV INFECTIONS; HUMANS; MALARIA; MALE; NEVIRAPINE; PLASMA; UGANDA;

EID: 84865350852     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dks207     Document Type: Article

References (43)

1. WHO. Malaria and HIV Interactions and Their Implications for Public Health Policy. 2004. http://www.who.int/hiv/pub/prev_care/malariahiv. pdf (24 May 2012, date last accessed).
2. Whitworth J, Morgan D, Quigley M et al. Effect of HIV-1 and increasing immunosuppression on malaria parasitaemia and clinical episodes in adults in rural Uganda: a cohort study. Lancet 2000; 356: 1051-6.
3. French N, Nakiyingi J, Lugada E et al. Increasing rates of malarial fever with deteriorating immune status in HIV-1-infected Ugandan adults. AIDS 2001; 15: 899-906.
4. Kublin JG, Steketee RW. HIV infection and malaria-understanding the interactions. J Infect Dis 2006; 193: 1-3.
5. Abu-Raddad LJ, Patnaik P, Kublin JG. Dual infection with HIV and malaria fuels the spread of both diseases in sub-Saharan Africa. Science 2006; 314: 1603-6.
6. Mermin J, Lule J, Ekwaru JP et al. Effect of co-trimoxazole prophylaxis on morbidity, mortality, CD4-cell count, and viral load in HIV infection in rural Uganda. Lancet 2004; 364: 1428-34.
7. Mermin J, Ekwaru JP, Liechty CA et al. Effect of co-trimoxazole prophylaxis, antiretroviral therapy, and insecticide-treated bednets on the frequency of malaria in HIV-1-infected adults in Uganda: a prospective cohort study. Lancet 2006; 367: 1256-61.
8. Omari AA, Gamble C, Garner P. Artemether-lumefantrine (six-dose regimen) for treating uncomplicated falciparum malaria. Cochrane Database Syst Rev 2005; issue 4: CD005564.
9. Djimde A, Lefevre G. Understanding the pharmacokinetics of Coartem. Malar J 2009; 8 Suppl 1: S4.
10. White N. Preventing antimalarial drug resistance through combinations. Drug Resist Updat 1998; 1: 3-9.
11. Ezzet F, Mull R, Karbwang J. Population pharmacokinetics and therapeutic response of CGP 56697 (artemether+benflumetol) in malaria patients. Br J Clin Pharmacol 1998; 46: 553-61.
12. Price RN, Uhlemann AC, van Vugt M et al. Molecular and pharmacological determinants of the therapeutic response to artemether-lumefantrine in multidrug-resistant Plasmodium falciparum malaria. Clin Infect Dis 2006; 42: 1570-7.
13. Fellay J, Marzolini C, Decosterd L et al. Variations in CYP3A activity induced by antiretroviral treatment in HIV-1 infected patients. Eur J Clin Pharmacol 2005; 60: 865-73.
14. Barry M, Mulcahy F, Merry C et al. Pharmacokinetics and potential interactions amongst antiretroviral agents used to treat patients with HIV infection. Clin Pharmacokinet 1999; 36: 289-304.
15. Ma Q, Okusanya OO, Smith PF et al. Pharmacokinetic drug interactions with non-nucleoside reverse transcriptase inhibitors. Expert Opin Drug Metab Toxicol 2005; 1: 473-85.
16. Khoo S, Back D, Winstanley P. The potential for interactions between antimalarial and antiretroviral drugs. AIDS 2005; 19: 995-1005.
17. German P, Parikh S, Lawrence J et al. Lopinavir/ritonavir affects pharmacokinetic exposure of artemether/lumefantrine in HIV-uninfected healthy volunteers. J Acquir Immune Defic Syndr 2009; 51: 424-9.
18. German P, Greenhouse B, Coates C et al. Hepatotoxicity due to a drug interaction between amodiaquine plus artesunate and efavirenz. Clin Infect Dis 2007; 44: 889-91.
19. Gasasira AF, Kamya M, Achan J et al. High risk of neutropenia in HIV-infected children following treatment with artesunate for uncomplicated malaria in Uganda. Clin Infect Dis 2008; 46: 985-91.
20. Kredo T, Mauff K, Van der Walt JS et al. Interaction between artemether-lumefantrine and nevirapine-based antiretroviral therapy in HIV-1-infected patients. Antimicrob Agents Chemother 2011; 55: 5616-23.
21. Ashley EA, Stepniewska K, Lindegardh N et al. How much fat is necessary to optimize lumefantrine oral bioavailability? Trop Med Int Health 2007; 12: 195-200.
22. Hanpithakpong W, Kamanikom B, Dondorp AM et al. A liquid chromatographic-tandem mass spectrometric method for determination of artesunate and its metabolite dihydroartemisinin in human plasma. J Chromatogr 2008; 876: 61-8.
23. Annerberg A, Singtoroj T, Tipmanee P et al. High throughput assay for the determination of lumefantrine in plasma. J Chromatogr 2005; 822: 330-3.
24. Almond LM, Edirisinghe D, Dalton M et al. Intracellular and plasma pharmacokinetics of nevirapine in human immunodeficiency virusinfected individuals. Clin Pharmacol Ther 2005; 78: 132-42.
25. Huang L, Parikh S, Lizak P et al. Pharmacokinetic interactions between the antiretroviral agent efavirenz and the antimalarial artemether-lumefantrine in healthy adults. ASTMH 2011. Poster no. 899. http://www.astmh.org/AM/Template.cfm?Section=Abstracts_and_Education1&Template=/CM/ContentDisplay.cfm&ContentID=3722 (25 May 2012, date last accessed).
26. FDA. Guidance for Industry: Drug Interaction Studies-Study Design, Data Analysis, and Implications for Dosing and Labelling. 2006.
27. Novartis Pharmaceuticals Corporation. Coartem (Artemether and Lumefantrine) Tablet: Human Prescription Drug Label. http://www. pharma.us.novartis.com/product/pi/pdf/coartem.pdf (9 August 2011, date last accessed).
28. White NJ, van Vugt M, Ezzet F. Clinical pharmacokinetics and pharmacodynamics and pharmacodynamics of artemetherlumefantrine. Clin Pharmacokinet 1999; 37: 105-25.
29. Ilett KF, Ethell BT, Maggs JL et al. Glucuronidation of dihydroartemisinin in vivo and by human liver microsomes and expressed UDP-glucuronosyltransferases. Drug Metab Dispos 2002; 30: 1005-12.
30. van Agtmael MA, Cheng-Qi S, Qing JX et al. Multiple dose pharmacokinetics of artemether in Chinese patients with uncomplicated falciparum malaria. Int J Antimicrob Agents 1999; 12: 151-8.
31. Ali S, Najmi MH, Tarning J et al. Pharmacokinetics of artemether and dihydroartemisinin in healthy Pakistani male volunteers treated with artemether-lumefantrine. Malar J 2010; 9: 275.
32. Na Bangchang K, Karbwang J, Thomas CG et al. Pharmacokinetics of artemether after oral administration to healthy Thai males and patients with acute, uncomplicated falciparum malaria. Br J Clin Pharmacol 1994; 37: 249-53.
33. Mordi MN, Mansor SM, Navaratnam V et al. Single dose pharmacokinetics of oral artemether in healthy Malaysian volunteers. Br J Clin Pharmacol 1997; 43: 363-5.
34. Lehmann JM, McKee DD, Watson MA et al. The human orphan nuclear receptor PXR is activated by compounds that regulate CYP3A4 gene expression and cause drug interactions. J Clin Invest 1998; 102: 1016-23.
35. Back D, Gibbons S, Khoo S. Pharmacokinetic drug interactions with nevirapine. J Acquir Immune Defic Syndr 2003; 34 Suppl 1: S8-14.
36. Faucette SR, Zhang TC, Moore R et al. Relative activation of human pregnane X receptor versus constitutive androstane receptor defines distinct classes of CYP2B6 and CYP3A4 inducers. J Pharmacol Exp Ther 2007; 320: 72-80.
37. Hariparsad N, Nallani SC, Sane RS et al. Induction of CYP3A4 by efavirenz in primary human hepatocytes: comparison with rifampin and phenobarbital. J Clin Pharmacol 2004; 44: 1273-81.
38. Xie W, Yeuh MF, Radominska-Pandya A et al. Control of steroid, heme, and carcinogen metabolism by nuclear pregnane X receptor and constitutive androstane receptor. Proc Natl Acad Sci USA 2003; 100: 4150-5.
39. Kokwaro G, Mwai L, Nzila A. Artemether/lumefantrine in the treatment of uncomplicated falciparum malaria. Exp Opin Pharmacother 2007; 8: 75-94.
40. Van Geertruyden JP, Menten J, Colebunders R et al. The impact of HIV-1 on the malaria parasite biomass in adults in sub-Saharan Africa contributes to the emergence of antimalarial drug resistance. Malar J 2008; 7: 134.
41. Ittarrat W, Pickard AL, Rattanasinganchan P et al. Recrudescence in artesunate-treated patients with falciparum malaria is dependent on parasite burden not on parasite factors. Am J Trop Med Hyg 2003; 68: 147-52.
42. Ezzet F, van Vugt M, Nosten F et al. Pharmacokinetics and pharmacodynamics of lumefantrine (benflumetol) in acute falciparum malaria. Antimicrob Agents Chemother 2000; 44: 697-704.
43. Riska P, Lamson M, MacGregor T et al. Disposition and biotransformation of the antiretroviral drug nevirapine in humans. Drug Metab Dispos 1999; 27: 895-901.